Cingulate Inc. Common Stock (CING) Stock Price

CINGStock
$4.36+14.74%52W
Market Cap$63.40M
P/E—
PEG Ratio—
Div yield—
Beta-0.89

CING Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-28.41%
Price vs S&P 500 (4W)-15.31%
VGM Score62.12

CING Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.56-$0.45+20.12%(+$0.11)
Q1 2026-$0.53-$0.95-80.38%(-$0.42)
Q4 2025-$1.55-$0.84+45.81%(+$0.71)
Q3 2025-$0.75-$1.35-79.52%(-$0.60)
Q2 2025-$0.82-$1.09-32.52%(-$0.27)

CING Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.10
4.10

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
CINGCingulate Inc. Common Stock
——B————$4.36
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Cingulate Inc. Common Stock

Cingulate Inc is a clinical-stage biopharmaceutical company developing treatments using its proprietary precision timed-release drug delivery platform. The company focuses on ADHD and anxiety disorders, where less frequent dosing could improve patient outcomes and medication adherence. Cingulate is also evaluating additional therapeutic applications for its platform technology.